Enalapril was patented in 1978 and came into medical use in 1984. Enalapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to enalaprilat following oral administration. Enalaprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Enalapril may be used to treat essential or renovascular hypertension and symptomatic congestive heart failure.

SynZeal Research offers all Enalapril related impurities which certified COA with all characterization data like IR, Mass, HPLC purity, NMR & TGA report. We also provide CMR, DEPT and detailed structure characterization report as per requirements. Enalapril related products are being used by major pharmaceutical companies across the globe for their ANDA/DMF filing.

For more information on our products custom synthesis, contact SynZeal today.

standards@synzeal.com  www.synzeal.com